Share price
$4.05
As of Apr 28, 2026
CTMX | NASDAQ
Cytomx Therapeutics, Inc.
Cytomx Therapeutics, Inc. (CTMX) | runway 35.2 months | financing risk lower | market cap $890.7M. Daily snapshot of financials, capital pressure, and recent...
Company websiteLast updated Apr 28, 2026
Market cap
$890.7M
Snapshot valuation
30D volume
6.3M shares
Rolling average daily volume
Runway
35.2 months
Estimated from precomputed burn and cash
Financing risk
N/A
Current liquidity and recent financing activity do not point to an immediate capital raise.
Snapshot summary
Runway: 35.2 months based on estimated burn.
Recent financing detected on Mar 18, 2026.
Financing signal: Current liquidity and recent financing activity do not point to an immediate capital raise.
Recent developments
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
e-Funded Warrants March 16, 2026 CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update March 16, 2026 CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer More News Making a difference by being different CytomX is a different kind of clinical-stage biopharmaceutical company – intent on revolutionizing the way we treat cancer. Ou
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
ssage"> In the news March 18, 2026 CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants March 16, 2026 CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants March 16, 2026 <
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
> March 16, 2026 CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants March 16, 2026 CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update March 16, 2026 CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
CytomX Therapeutics, Inc. 8-K 2026-03-19
8-K filed on 2026-03-19.
CytomX Therapeutics, Inc. 424B5 2026-03-18
424B5 filing submitted on 2026-03-18.
Related screens
Low cash runway companies
Companies screening with the shortest estimated runway based on precomputed burn and cash snapshots.
High burn rate companies
Companies with the highest estimated trailing cash burn across the monitored issuer set.
Recent financing disclosures
Companies with recent financing activity, capital raises, or post-balance-sheet funding events.
Pre-market filings
Companies with recent filings or disclosures posted before the market open.
Related companies
Recent documents
CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
e-Funded Warrants March 16, 2026 CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update March 16, 2026 CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer More News Making a difference by being different CytomX is a different kind of clinical-stage biopharmaceutical company – intent on revolutionizing the way we treat cancer. Ou
Apr 21, 2026Open source
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
h3> March 18, 2026 CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants March 16, 2026 CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants March 16, 2026 CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update March 16, 2026 <a href="https://ir.c
Apr 21, 2026Open source
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
ssage"> In the news March 18, 2026 CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants March 16, 2026 CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants March 16, 2026 <
Apr 21, 2026Open source
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
> March 16, 2026 CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants March 16, 2026 CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update March 16, 2026 CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Apr 21, 2026Open source
Premium analysis
Full filing analysis and proprietary signal detail
Detailed impact scoring, historical financial trends, full filing analysis, premium alerts, and proprietary signal explanations stay behind login and subscription.
Full filing analysis with event-level impact scoring
Historical financial trends and runway context
Detailed signal breakdowns and proprietary explanations
Premium alerts, filters, and watchlist workflows
Deeper financing and dilution analysis
Timeline context across filings and disclosures